CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.
Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...
Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...
RADNOR, Pa. and PHILADELPHIA, Oct. 15, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and ...
As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...
Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy manufacturing. The collaboration merges Avantor’s bioprocessing expertise ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback